Determination, purity assessment and chiral separation of levodopa methyl ester in bulk and formulation pharmaceuticals

Biomedical Chromatography

Volumn 20, Issue 9, 2006, Pages 904-910

  Wang, Jie ^a,b   Fang, Yuzhi ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

Author keywords

3 methoxytyrosine; Electrochemical detection; High performance liquid chromatography; Levodopa; Levodopa methyl ester; Tyrosine

Indexed keywords

AMINO ACIDS; CHEMICAL DETECTION; CHIRALITY; DRUG DOSAGE; ENANTIOMERS; ESTERS; POTASSIUM COMPOUNDS; SODIUM CHLORIDE; TITRATION; VOLTAMMETRY;

3-METHOXYTYROSINE; BULK DRUGS; CHIRAL SEPARATIONS; ELECTROCHEMICAL DETECTION; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC METHOD; LEVODOPA; LEVODOPA METHYL ESTER; PURITY ASSESSMENT; TYROSINE;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

3 O METHYLDOPA; ACETONITRILE; EDETIC ACID; LEVODOPA; LEVODOPA METHYL ESTER; METHANOL; PHOSPHORIC ACID; POTASSIUM DIHYDROGEN PHOSPHATE; SODIUM CHLORIDE; TYROSINE;

ACCURACY; ARTICLE; CHIRALITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG IMPURITY; DRUG PURITY; ELECTROCHEMICAL DETECTION; ELUTION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LINEAR REGRESSION ANALYSIS; PH; POTENTIOMETRIC TITRATION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE;

EID: 33748941282     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.617     Document Type: Article

References (23)

1. Badawy SS, Issa YM and Tag-Eldin AS. Potentiometric determination of L-dopa, carbidopa, methyldopa and aspartame using a new trinitrobenzenesulfonate selective electrode. Electroanalysis 1996; 8: 1060.
2. Bodor NS, Sloan KB and Hussain AA. Novel, transient pro-drug forms of L-dopa useful in the treatment of Parkinson's disease. US patent no. 3,939,253, February 1976.
3. Bodor N, Sloan KB and Hussain AA. Novel, transient, pro-drug forms of L-Dopa, US patent no. 4,035,507, July 1977.
4. Biryol I, Özkan SA and Sentürk Z. Determination of levodopa in tablets based on voltammetric oxidation at platinum and glassy carbon electrodes. Acta Polonia Pharmaceutica 1995; 52(5): 365.
5. Britsh Pharmacopoeia, Vol. I. HMSO: London, 2004; 1158.
6. Britsh Pharmacopoeia, Vol. II. HMSO: London, 2004; 2538.
7. Cooper DR, Marrel C, Testa B, Waterbeemd HVD, NJenner NQP and Marsden CD. L-Dopa methyl ester - a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clinical Neuropharmacology 1984; 7(1): 89.
8. Cotzias GC, Papavasilou PS and Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. The New England Journal of Medicine 1969; 280: 337.
9. Dolezalova M and Tkaczykova M. Direct high-performance liquid chromatographic determination of the enantiomeric purity of levodopa and methyldopa: comparison with pharmacopoeial polarimetric methods. Journal of Pharmaceutical and Biomedical Analysis 1999; 19: 555.
10. Fix JA, Alexander J, Cortese M, Engle K, Leppert P and Repta AJ. Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption. Pharmaceutical Research 1989; 6(6): 501.
11. Hartmann C, Massart DL and McDowall RD. An analysis of the Washington Conference Report on bioanalytical method validation. Journal of Pharmaceutical and Biomedical Analysis 1994; 12(11): 1337.
12. Honda S, Araki Y, Takahashi M and Kakehi K. Spectrofluorimetric determination of catecholamines with 2-cyanoacetamide. Analytica Chimica Acta 1983; 149: 297.
13. Juncos JL, Mouradian MM, Fabbrini G, Serrati C and Chasel TN. Levodopa methyl ester treatment of Parkinson's disease. Neurology 1987; 37:1242.
14. Koshimura K, Ohue T, Akiyama Y, Itoh A and Miwa S. L-Dopa administration enhances exocytotic dopamine release in vivo in the rat striatum. Life Sciences 1992; 51(11): 747.
15. Lotti VJ and Porter CC. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. Journal of Pharmacology and Experimental Therapy 1970; 172(2): 406.
16. Rondelli I, Acerbi D, Mariotti F and Ventura P. Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B 1994; 653: 17.
17. Schieffer GW. Reversed-phase high-performance liquid chromatographic investigation of levodopa preparations II: levodopa determination. Journal of Pharmaceutica; Science 1979; 68(10): 1299.
18. Steiger MJ, Stocchi F, Carta A, Ruggieri, Agnoli A, Quinn NP and Marsden CD. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon 'off' periods in Parkinson's disease. Clinical Neuropharmacology 1991; 14(3): 241.
19. Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L and Ruggieri S. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. Functional Neurology 1994; 9(5): 259.
20. Tolokan A, Klebovich I, Baloghnemes K and Horvai G. Automated determination of levodopa and carbidopa in plasma by high-performance liquid chromatography electrochemical detection using an on-line flow injection analysis sample pretreatment unit. Journal of Chromatography B 1997; 698: 201.
21. United States Pharmacopoeia. USP 28. United States Pharmacopoeia Convention: Rockville, MD, 2005; 1121 and 2622.
22. Wang J, Zhou Y, Wang AF, He PG and Fang YZ. Determination of levodopa methyl ester and its metabolites in rat serum by CZE with amperometric detection. Analytical and Bioanalytical Chemistry 2005, 382: 198.
23. Wu G. The determination of levodopa in plasma by HPLC: a cautionary note. Chromatographia 2000; 52: 371.